Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.78, no.1, pp.143-150, 2016 (SCI-Expanded) identifier identifier identifier


The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer.